Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis

RET/PTC1-Driven Neoplastic Transformation and Proinvasive Phenotype of Human Thyrocytes Involve Met Induction and β-Catenin Nuclear Translocation

(2015) Giuliana Cassinelli et al.   NEOPLASIA

Cabozantinib in Progressive Medullary Thyroid Cancer

(2013) Rossella Elisei et al.   JOURNAL OF CLINICAL ONCOLOGY

Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models

(2011) Martin Bergstrand et al.   AAPS Journal

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

(2011) Razelle Kurzrock et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

Increased Expression of Vascular Endothelial Growth Factor and Its Receptors, VEGFR-1 and VEGFR-2, in Medullary Thyroid Carcinoma

(2010) Clarissa Capp et al.   THYROID

Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions

(2009) Radojka M. Savic et al.   AAPS Journal